Loss of FHIT expression in cervical carcinoma cell lines and primary tumors.

David L. Greenspan, Denise C. Connolly, Rong Wu, R.y. Lei, Joshua T Vogelstein, Young Tae Kim, J E Mok, Núbia Muñóz, F. Xavier Bosch, K. V. Shah, Kathleen R. ChoPubMed 1997

TL;DR

This study investigates the role of the FHIT gene in cervical cancer by examining its expression at both the mRNA and protein levels. They found that FHIT expression is frequently lost or altered in cervical cancer cell lines and primary tumors, suggesting FHIT is a crucial tumor suppressor gene in cervical tumorigenesis.

What Problem Does This Paper Address?

Cervical cancer is a major health concern for women worldwide, and its development is strongly linked to human papillomavirus (HPV) infection. While HPV's oncoproteins are known to disrupt cell cycle regulation by interacting with tumor suppressors like p53 and pRB, it's understood that HPV infection alone isn't sufficient for cancer development. This implies that other genetic events, such as the inactivation of tumor suppressor genes, are critical. Previous research had identified frequent allelic deletions on chromosome 3p in cervical carcinomas, and a candidate tumor suppressor gene, FHIT, was mapped to this region (3p14.2). Furthermore, FHIT is located within a fragile site (FRA3B) where HPV DNA has been found integrated. However, the precise significance of abnormal FHIT transcripts and the molecular mechanisms behind their origin in cervical cancer remained unclear. This paper aims to clarify the role of FHIT by comprehensively analyzing its mRNA and protein expression in cervical cancer cell lines, primary tumors, and normal tissues.

Methods

The researchers employed a multi-pronged approach to assess FHIT expression:

  • Reverse Transcription Polymerase Chain Reaction (RT-PCR): This technique was used to detect and analyze FHIT mRNA. Both nested and non-nested RT-PCR strategies were utilized to amplify FHIT cDNA from various cell lines and tissues. This allowed them to identify transcripts of the expected size and sequence, as well as aberrant (altered) transcripts. To ensure the quality of RNA samples, they also performed RT-PCR for GAPDH, a housekeeping gene.
  • Northern Blot Analysis: This method was used to confirm and quantify FHIT mRNA levels, providing a more global view of gene expression compared to RT-PCR, which can be more sensitive to specific transcript variants.
  • Immunohistochemistry: This technique was crucial for visualizing FHIT protein expression directly within tissue samples and cell lines. They used a specific anti-Fhit antiserum and developed a scoring system to quantify the intensity and extent of protein staining. Blocking experiments with purified FHIT protein were performed to confirm the specificity of the antibody.

Datasets

The study utilized the following datasets:

  • Cervical Carcinoma Cell Lines: Seven established cervical carcinoma cell lines (HT-3, SiHa, C-4II, CaSki, C-33a, HeLa, and ME-180) were used. Some of these lines were known to be HPV-positive or negative and to have mutant or wild-type p53 alleles.
  • Primary Cervical Carcinomas: A total of 35 invasive squamous carcinomas of the cervix were analyzed. This included 34 primary tumors and 1 metastatic lesion. Frozen tissue was available for 25 tumors, and formalin-fixed, paraffin-embedded material was available for 33.
  • Normal Tissues:
    • Primary keratinocytes cultured from fresh human foreskins and cervix were used as a normal epithelial control.
  • Various normal human tissues (brain, lung, liver, kidney, colon, thyroid, cervix, ovary, and myometrium) were obtained from surgical specimens for comparison.

Key Insights and Ideas

  • FHIT is frequently altered in cervical cancer: The most striking finding is the high prevalence of aberrant FHIT transcripts and loss of FHIT protein expression in cervical cancer. This strongly implicates FHIT as a key player in the development of this malignancy.
  • Aberrant transcripts correlate with protein loss: The study demonstrates a clear link between the presence of abnormal FHIT mRNA and the absence or significant reduction of FHIT protein. This suggests that these transcript alterations directly lead to functional loss of the protein.
  • FHIT is a tumor suppressor candidate: The pattern of FHIT alterations (loss or reduction in cancer, but not in normal tissues) aligns with the expected behavior of a tumor suppressor gene. The fact that these alterations occur in both HPV-positive and HPV-negative cervical cancers suggests FHIT inactivation is a critical event, potentially independent of HPV status in some cases.
  • HPV integration at FHIT locus is significant: The paper highlights that FHIT is located at a fragile site (FRA3B) where HPV DNA can integrate. This integration could directly disrupt FHIT gene function, providing a molecular link between HPV infection and FHIT inactivation.
  • FHIT is not a non-specific marker of genomic instability: The authors note that FHIT alterations are common in cervical cancer but less so in other cancers like colorectal cancer. This suggests that FHIT inactivation is a specific event in cervical tumorigenesis, rather than a general consequence of widespread genomic instability.

Key Results

  • Aberrant FHIT transcripts: 6 out of 7 cervical carcinoma cell lines and 17 out of 25 (68%) primary cervical carcinomas showed aberrant FHIT transcripts detected by RT-PCR.
  • Reduced/Absent FHIT mRNA: Northern blot analysis confirmed reduced or absent FHIT mRNA expression in cervical carcinoma cell lines, particularly those with aberrant RT-PCR products.
  • Reduced/Absent FHIT protein: Immunohistochemical analysis revealed marked reduction or loss of FHIT protein in 25 out of 33 (76%) primary cervical carcinomas.
  • Correlation between mRNA and protein: In cell lines and tumors with exclusively aberrant or absent FHIT transcripts by RT-PCR, FHIT protein expression was always markedly reduced or absent.
  • Normal tissues express FHIT: Cultured keratinocytes and all normal tissues evaluated showed FHIT transcripts of the expected size and sequence, and strong FHIT protein immunoreactivity in normal cervical epithelium.

Limitations and Future Work

  • Function of FHIT protein: The exact function of the human FHIT protein remains unknown. The paper notes its similarity to a yeast enzyme involved in diadenosine tetraphosphate hydrolysis, but further investigation is needed to understand its precise role in cellular processes.
  • Origin of full-length transcripts in tumors: In some primary tumors, both full-length and aberrant FHIT transcripts were detected, along with significant FHIT protein expression. The authors suggest that these full-length transcripts might originate from contaminating normal cells or represent transcripts with aberrant sequences that still encode functional protein. Further studies are needed to differentiate these possibilities.
  • In vivo function: The paper calls for further analysis to assess the in vivo function of FHIT in normal, preneoplastic, and neoplastic tissues. This would involve functional studies to confirm its tumor suppressor activity and understand its mechanisms of action in the context of cervical tumorigenesis.
  • Mechanism of FHIT inactivation: While HPV integration at FRA3B is suggested, other mechanisms of FHIT inactivation (e.g., point mutations, epigenetic silencing) in both HPV-positive and HPV-negative tumors warrant further investigation.

Summary updated

Abstract

Allelic deletions involving the short arm of chromosome 3 (3p13-21.1) have been observed frequently in cervical carcinomas. Recently, a candidate tumor suppressor gene, FHIT (Fragile Histidine Triad), was cloned and mapped to this chromosomal region (3p14.2). Abnormal FHIT transcripts have been identified previously in a variety of tumor cell lines and primary carcinomas, although their significance and the molecular mechanisms underlying their origin remain incompletely defined. In addition, integration of human papillomavirus DNA has been identified at a fragile site (FRA3B) within the FHIT locus in cervical cancer. These observations motivated us to evaluate FHIT mRNA and protein expression in cervical cancer cell lines, primary cervical carcinomas, and normal tissues. Transcripts of the expected size and sequence were the predominant species identified by reverse transcription (RT)-PCR in cultured keratinocytes and all normal tissues evaluated. In contrast, aberrant FHIT transcripts were readily demonstrated in 6 of 7 cervical carcinoma cell lines and 17 of 25 (68%) primary cervical carcinomas. Northern blot analyses demonstrated reduced or absent FHIT expression in the cervical carcinoma cell lines, particularly those with aberrant RT-PCR products. Immunohistochemical analysis of Fhit expression in cervical tissues revealed strong immunoreactivity in nonneoplastic squamous and glandular cervical epithelium and marked reduction or loss of Fhit protein in 25 of 33 (76%) primary cervical carcinomas. In those cervical cancer cell lines and primary tumors with exclusively aberrant or absent FHIT transcripts by RT-PCR, Fhit protein expression was always markedly reduced or absent. The frequent alterations in FHIT expression in many cervical carcinomas, but not in normal tissues, suggest that FHIT gene alterations may play an important role in cervical tumorigenesis.
BibTeX
@inproceedings{greenspan1997loss,
  author = {David L. Greenspan and Denise C. Connolly and Rong Wu and R.Y. Lei and Joshua T Vogelstein and Young Tae Kim and J E Mok and Núbia Muñóz and F. Xavier Bosch and K. V. Shah and Kathleen R. Cho},
  title = {{Loss of FHIT expression in cervical carcinoma cell lines and primary tumors.}},
  booktitle = {PubMed},
  year = {1997},
}
Figure